X

Vous n'êtes pas connecté

Maroc Maroc - FINANCIALPOST.COM - A La Une - 31/Jan 01:16

Enveric Biosciences Announces Pricing of $5 Million Public Offering

CAMBRIDGE, Mass. — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the pricing of a public offering of an aggregate of 1,666,666 shares of its common stock (or common stock equivalents […]

Articles similaires

Sorry! Image not available at this time

Enveric Biosciences receives notice of allowance from USPTO for its drug candidate EB─003 to treat mental health disorders

pharmabiz.com - 08:22

Enveric Biosciences, a Naples─headquartered biotechnology company dedicated to the development of novel neuroplastogenic small─molecule...

A connection has been identified between the health of various organs and mental health 16:24

socialbites.ca - 23/Jan 13:53

An international team of scientists has found that poor organ health in the body can contribute to poor mental health. The study was published in the...

Sorry! Image not available at this time

These 8 mental diseases share the same genetic cause

knowridge.com - 25/Jan 11:06

Psychiatric disorders often overlap, with shared symptoms making diagnosis challenging. Conditions like depression and anxiety, schizophrenia and...

Sorry! Image not available at this time

Worrying shortage of antipsychotic drugs in Cyprus

cyprus-mail.com - 29/Jan 14:17

Cyprus is rapidly running out of the antipsychotic drug Seroquel with the higher dosages especially being in short supply since early October, the...

Sorry! Image not available at this time

FDA Approves Symbravo (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

drugs.com - 31/Jan 20:01

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment...

Sorry! Image not available at this time

Stealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth Syndrome

drugs.com - 23/Jan 18:01

NEEDHAM, Mass., Jan. 23, 2025 /PRNewswire/ — Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a clinical-stage...

D-Wave Announces Successful Completion of $150 Million At-the-Market Equity Offering

thequantumdaily.com - 23/Jan 15:57

Insider Brief PRESS RELEASE — D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”), a leader in quantum computing systems, software,...

Innovative research links biometric data to mood prediction in shift workers

news.medical.net - 22/Jan 06:51

The CORONA virus pandemic also brought about a pandemic of mental illness. Approximately one billion people worldwide suffer from various psychiatric...

Brain Implant to Treat Mood Disorders Using Ultrasound

medindia.net - 22/Jan 18:17

A brain implant using ultrasound shows promise for treating mood disorders like depression and anxiety with precision and minimal invasiveness.

Sorry! Image not available at this time

Keymed Biosiences’ Out-Licensing Transaction With Timberlyne Therapeutics Inc.

globallegalchronicle.com - 28/Jan 00:00

Clifford Chance advised Keymed Biosciences on the deal. Timberlyne Therapeutics, Inc. announced its US$180 million Series A financing to advance the...